Wavera Matrix.
Continuous clinical evaluation across 41 disease sites and 280+ oncology cases. Every recommendation is audited against guideline-grounded rubrics, with real-world edge cases included on purpose.
A representative sample of our case library.
Hover a cell to inspect the case — prompt, rubric, required rationale, and safety flags. The matrix below is a curated cross-section of the broader internal library we evaluate against; it is meant to illustrate the shape of our coverage, not to enumerate every case.
- 01Consider blinatumomab or inotuzumab ozogamicin as bridge.REQUIRED
- 02Evaluate for CD19 CAR-T (tisagenlecleucel or brexucabtagene).REQUIRED
FDA · NDC · RxNorm · every barcode, every vial.
Wavera Inventory is validated against the complete FDA NDC database — 131,302 drug products, 7,457 injectable vials. Every barcode parses. Every NDC resolves to a RxNorm ingredient. Every dose calculation traces back to an FDA-published package description. Zero hallucinations — if the concept isn't in RxNorm or the NDC isn't in the FDA registry, we refuse to guess.
Four pillars · one evidence trail.
See the full evaluation suite?
We'll walk you through the hard cases.
Request read access to the live Matrix dashboard — case by case, rubric by rubric, model by model.